Holen Sie sich die Stockscreener-App
36.04
1.48%
-0.54
Handel nachbörslich:
36.04
Schlusskurs vom Vortag:
$36.58
Offen:
$36.21
24-Stunden-Volumen:
314.05K
Relative Volume:
0.62
Marktkapitalisierung:
$1.01B
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-5.9276
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
-0.39%
1M Leistung:
+16.48%
6M Leistung:
+70.08%
1J Leistung:
+66.24%
1-Tages-Spanne:
$35.53
$37.12
1-Wochen-Bereich:
$35.53
$38.38
52-Wochen-Spanne:
$12.21
$38.38
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
36.04 | 1.02B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Using fundamentals and technicals on AnaptysBio Inc.Portfolio Value Report & Intraday High Probability Setup Alerts - newser.com
Can AnaptysBio Inc. stock beat market expectations this quarterWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
How AnaptysBio Inc. stock reacts to job market data2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Identifying reversal signals in AnaptysBio Inc.2025 Momentum Check & Weekly Breakout Watchlists - newser.com
Real time alert setup for AnaptysBio Inc. performance2025 Biggest Moves & Precise Entry and Exit Recommendations - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarksWeekly Stock Recap & High Accuracy Trade Alerts - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Why AnaptysBio Inc. stock is recommended by analystsEarnings Summary Report & Expert Curated Trade Setup Alerts - newser.com
Why AnaptysBio Inc. (AN6) stock could be top winnerJuly 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
Is AnaptysBio Inc. stock attractive for growth ETFsWeekly Risk Summary & Safe Entry Momentum Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock worth holding before Fed meetingQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Can AnaptysBio Inc. stock weather global recessionJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Will AnaptysBio Inc. stock deliver shareholder valueWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com
How rising interest rates impact AnaptysBio Inc. stock2025 Pullback Review & AI Driven Price Forecasts - newser.com
AnaptysBio FY2026 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
Risk adjusted return profile for AnaptysBio Inc. analyzedQuarterly Performance Summary & Verified Stock Trade Ideas - newser.com
How AnaptysBio Inc. stock benefits from tech adoptionEarnings Trend Report & Long-Term Growth Portfolio Plans - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com
How currency fluctuations impact AnaptysBio Inc. stock2025 Year in Review & Stock Portfolio Risk Control - newser.com
Does AnaptysBio Inc. show high probability of reboundJuly 2025 Fed Impact & Weekly High Return Stock Forecasts - newser.com
What drives AnaptysBio Inc AN6 stock pricePrice Support Zones & Free Unlock Stock Analysis - earlytimes.in
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio FY2025 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades - Yahoo Finance
Moody Aldrich Partners LLC Sells 23,130 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Applying big data sentiment scoring on AnaptysBio Inc.Market Activity Recap & Weekly Sector Rotation Insights - newser.com
Published on: 2025-10-31 05:16:43 - newser.com
Can AnaptysBio Inc. stock sustain revenue growthTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
Published on: 2025-10-31 00:12:04 - newser.com
Will AnaptysBio Inc. stock benefit from sector rotation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
What analysts say about AnaptysBio Inc stockInsider Trading Compliance & Small Budget Trading Portfolio - earlytimes.in
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):